Coronary artery disease Medical Services in China

Coronary artery disease (CAD), commonly known as coronary heart disease, is a chronic condition characterized by the narrowing or blockage of the coronary arteries—typically due to atherosclerotic plaque buildup—leading to myocardial ischemia, angina pectoris, acute coronary syndromes, and potentially myocardial infarction. Risk factors include hypertension, dyslipidemia, diabetes mellitus, smoking, obesity, and sedentary lifestyle. Diagnosis relies on clinical evaluation, electrocardiography, stress testing, coronary angiography, and increasingly, non-invasive coronary computed tomography angiography (CCTA) and intravascular ultrasound (IVUS). Management encompasses pharmacotherapy (antiplatelets, statins, beta-blockers, ACE inhibitors), lifestyle modification, percutaneous coronary intervention (PCI) with drug-eluting stents, and coronary artery bypass grafting (CABG) for complex multivessel disease.

China offers compelling advantages for CAD treatment: its tier-1 cardiovascular centers—such as Fuwai Hospital (National Center for Cardiovascular Diseases) and Shanghai Ruijin Hospital—rank among Asia’s most advanced, with internationally trained interventional cardiologists performing over 100,000 PCI procedures annually. State-of-the-art hybrid operating rooms, robotic-assisted PCI platforms, and real-time fractional flow reserve (FFR) guidance ensure precision and safety. Five-year survival rates for high-risk CABG patients exceed 85%, supported by robust clinical registries and outcomes tracking. Crucially, costs for comprehensive CAD care—including diagnostics, stenting, or bypass surgery—are typically 40–60% lower than in the US or Western Europe, without compromising evidence-based protocols or accreditation standards (JCI- or CNAS-certified facilities).

As a dedicated medical tourism agency, we facilitate seamless access to these resources for international patients: verifying physician credentials, coordinating appointments at vetted hospitals, providing itemized, transparent pricing in advance, arranging visa support, medical translation, accommodation, and post-procedure follow-up—all under one coordinated service framework.

Treatment Options & Itemized Cost Breakdown: Coronary Artery Disease (CAD)

Non-Surgical / Conservative Management

*Target criteria:* Stable angina, low SYNTAX score (<22), no high-risk features (e.g., LVEF <40%, recurrent ischemia on meds).

• •Core Medications (30-day supply, tiered pricing):

- *Tier 2 (Branded domestic):* Aspirin (¥15), Atorvastatin (¥45), Metoprolol (¥62), Nitrate (¥78) → Total: ¥200 (~$28) - *Tier 3 (Imported):* Clopidogrel (¥198), Rosuvastatin (¥220), Rivaroxaban (if indicated, ¥310) → Total: ¥728 (~$102)

• •Essential Diagnostics (per episode):

- Echocardiogram (TTE): ¥320 ($45) - Stress test (treadmill ECG): ¥450 ($63) - Coronary CTA (64-slice): ¥1,200 ($169)

Surgical / Interventional Procedures

*Eligibility:* ≥70% stenosis in ≥1 major epicardial vessel, unstable angina/NSTEMI/STEMI, SYNTAX score ≥22 or left main disease.

• •PCI (Percutaneous Coronary Intervention):

- *Multi-vessel:* +¥15,000–¥25,000 ($210–$350) per additional stent - *Pre-op workup:* Coronary angiography (¥8,500/$1,195), renal function panel (¥120/$17), coagulation profile (¥95/$13)

• •CABG (Coronary Artery Bypass Grafting):

- Off-pump or arterial grafts: +¥20,000–¥35,000 ($280–$490) - Pre-op: Cardiopulmonary exercise test (¥1,200/$169), CT angiography (¥1,200/$169), carotid ultrasound (¥380/$53)

Special/Complex Condition Management

• •Left Main CAD or severe multivessel disease with diabetes/LVEF <35%: CABG preferred; cost range ¥105,000–¥145,000 ($1,475–$2,040) including ICU stay (¥2,800/day).
• •Chronic Total Occlusion (CTO): PCI with specialized equipment (microcatheters, IVUS): +¥18,000–¥32,000 ($250–$450) over standard PCI.
• •Refractory angina (no revascularization option): Enhanced External Counterpulsation (EECP): ¥12,000/course (20 sessions, $169).

Quick Selection Guide

• •<65 years, high SYNTAX, no comorbidities: CABG (long-term survival advantage; budget ≥$1,500).
• •65–75 years, single-vessel, moderate budget ($500–$1,000): Domestic-stent PCI + Tier 2 meds.
• •>75 years, frail, multiple comorbidities (COPD, CKD): Conservative management (Tier 1 meds + stress test monitoring; budget <$100).
• •STEMI within 90 min of arrival: Immediate PCI (imported stent justified; total cost ~$1,200–$1,500 including angiography and ICU).
• •Diabetes + multivessel CAD: CABG over PCI (superior 5-year outcomes; allocate $1,600+).